NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 244 shares, a decline of 50.5% from the December 31st total of 493 shares. Based on an average daily trading volume, of 237 shares, the short-interest ratio is currently 1.0 days. Based on an average daily trading volume, of 237 shares, the short-interest ratio is currently 1.0 days.
Institutional Investors Weigh In On NewAmsterdam Pharma
An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC lifted its position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) by 1.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 245,000 shares of the company’s stock after buying an additional 3,043 shares during the quarter. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 at the end of the most recent quarter.
NewAmsterdam Pharma Stock Down 2.6%
NewAmsterdam Pharma stock opened at $22.28 on Thursday. The company has a 50 day moving average price of $24.52 and a 200-day moving average price of $20.17. NewAmsterdam Pharma has a fifty-two week low of $5.45 and a fifty-two week high of $29.99.
About NewAmsterdam Pharma
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.
Further Reading
- Five stocks we like better than NewAmsterdam Pharma
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
